



2026 iCARDIO Alliance Global Implementation Guidelines on Heart Failure

Vijay Chopra* (India), William T. Abraham (USA), Offer Amir (Israel), Stefan D. Anker (Germany), John J. Atherton (Australia), Fernando Bacal (Brazil), Ralph Stephan von Bardeleben (Germany), Dulce Brito (Portugal), Lucrecia Maria Burgos (Argentina), Javed Butler (USA), Maria Rosa Costanzo (USA), Albertino Damasceno (Mozambique), Justin A. Ezekowitz (Canada), Ishaque Hameed (USA), Sivadasanpillai Harikrishnan (India), Anuradha Lala (USA), Ileana L. Piña (USA), Clara Saldarriaga (Colombia), David Sim (Singapore), John R. Teerlink (USA), Nqoba Tsabedze (South Africa), Hiroyuki Tsutsui (Japan), Jing Yu (China), Yuhui Zhang (China), Mohammad Zubaid (Kuwait), Nikhil Balankhe (India), John G.F. Cleland (UK), Gemma Figtree (Australia), Gerasimos Filippatos (Greece), Marat Fudim (USA), Habib Gamra (Tunisia), Juan Esteban Gomez-Mesa (Colombia), Martha Gulati (USA), James L. Januzzi (USA), Marvin A. Konstam (USA), JoAnn Lindenfeld (USA), Robert J. Mentz (USA), Rhonda Monroe (USA), Elijah Ogola (Kenya), Fausto J. Pinto (Portugal), Girish C. Rajadhyaksha (India), Carlos E. Ramos (Honduras), Giuseppe Rosano (Italy), Victor Rossel (Chile), Naoki Sato (Japan), P. Christian Schulze (Germany), Andrew Sindone (Australia), Kadhim Sulaiman (Oman), Muthiah Vaduganathan (USA), Harriette G.C. Van Spall (Canada), Dirk J. van Veldhuisen (Netherlands), Stephan von Haehling (Germany), Tzung-Dau Wang (Taiwan), Pepe Zamorano (Spain), Michael Böhm[#] (Germany), Andrew J.S. Coats[#] (Australia), Shelley Zieroth^{*#} (Canada)

[#]Drs. Böhm, Coats and Zieroth would like to be considered joint senior authors.

Note: All authors were either writing task force members or active guideline reviewers. The author affiliations are listed at the end of the document.

Abstract

This is the updated 2026 version of the iCARDIO Alliance Global Implementation Guidelines on Heart Failure – originally published in 2025. In these guidelines, we aim to consider inconsistencies in healthcare access, varying infrastructure, resource constraints and diverse local practices as well as practical and political issues that restrict the global applicability of currently available guidelines. There is a need for universal recommendations that address the unique challenges faced by patients and healthcare providers worldwide. Our iCARDIO Alliance Global Implementation Guidelines emphasize the incorporation of novel therapies, while integrating standard of care with the most up-to-date evidence to enable clinicians to optimize patient care. This document is about heart failure (HF), including acute and chronic heart failure, heart failure with reduced ejection fraction and heart failure with preserved ejection fraction as well as HF with improved ejection fraction and cardiomyopathies. Context-specific recommendations tailored to individual patient needs are highlighted providing a thorough evaluation of the risks, benefits, and overall value of each therapy, aiming to establish a standard of care that improves patient outcomes and reduces the burden of hospitalization in this susceptible population. These guidelines provide evidence-based recommendations that represent a group consensus considering the many other published guidelines that have reviewed many of the issues discussed here, but they also make new recommendations where new evidence has recently emerged. Most importantly these guidelines also provide recommendations on a number of issues where resource limitations may put constraints on the care provided to HF patients. Such “economic adjustment” recommendations aim to provide guidance for situations when “Resources are somewhat limited” or when “Resources are severely limited”. Hence, this document presents not only a comprehensive but also concise set of recommendations to guide all aspects of HF management with a unified strategy for the pharmacological, non-pharmacological, invasive and interventional management of this significant global health challenge that is applicable to the needs of healthcare around the globe.

Key words: heart failure; chronic heart failure; acute heart failure; therapy; guidelines; iCARDIO Alliance.

Received: 18 August 2026; Accepted: 18 August 2026.

*Correspondence to: Vijay Chopra, MD, Heart Failure Programme and Research, Max Super Specialty Hospital, Press Enclave Road, Mandir Marg, Saket Institutional Area, Saket, New Delhi, 110017, India. E-mail: chopravk@gmail.com
Shelley Zieroth, MD, Y3014409 Tache Avenue, Winnipeg, Manitoba, R2H2A6, Canada. E-mail: szieroth@sbggh.mb.ca

Preamble

The International CARDIO Alliance to Improve Disease Outcomes (iCARDIO Alliance: <https://icardioalliance.org>) aims to gather leading cardiovascular societies around the globe as partner organizations to improve the quality of cardiovascular care, from prevention and diagnosis to treatment and follow up. The goal of these global implementation guidelines is to achieve global representation in writing panels and to produce concise and practical guidelines applicable to all cardiovascular care worldwide. In addition to clinical practice guidelines developed by other medical associations, the recommendations by iCARDIO Alliance take into account resource availability on at least 3 economic levels (with no economic consideration; resources somewhat limited; resources severely limited).

Introduction

Heart failure (HF) is a leading public health challenge, with over 64 million prevalent cases worldwide.¹ Studies from the USA have projected a 46% increase in HF cases from 2012 to 2030 due to ageing population, with a significant rise in HF with preserved ejection fraction (HFpEF). In addition, health-care costs associated with HF are expected to rise by approximately 127%.² By 2050, nearly 11 million adults are expected to be affected by HF in the USA.³ To mitigate this growing public health threat, it is essential to improve the understanding of this condition, promote lifestyle modifications, and implement early detection strategies, and treatment modalities. In 1994, the US Agency for Healthcare Policy and Research published the first clinical guidelines for managing HF, which were subsequently followed by the American Heart Association and the American College of Cardiology guidelines in 1995.^{4,5} Since then, several countries- and region-specific guidelines have emerged, predominantly from Western countries, which influence decision-making across multiple stakeholders, including patients, clinicians, healthcare leaders, and payers.⁶⁻¹⁷ However, uniform implementation of these guidelines across all regions remains a challenge due to variations in infrastructure and local practices.¹⁸ Current evidence suggests that guideline-directed medical therapies (GDMT) significantly decrease mortality and hospitalizations among individuals with HF, particularly HF with reduced ejection fraction (HFrEF), and are therefore recommended as highly cost-effective interventions by the Disease Control Priorities Project.¹⁹ Despite strong evidence supporting GDMT, its utilization remains limited in low- and middle-income countries (LMIC), where barriers at the health system, provider, and patient levels contribute to a 22% to 58% higher 1-year mortality rate compared to high-income countries.^{1,20,21} Furthermore, there is a lack of substantial data to ascertain the relevance of current guidelines to diverse populations across the globe. Often, where evidence is strong, the recommendations are unlikely to adjust to accommodate economic constraints and availability.¹⁸ For example, in the Middle East where economic constraints may not play a big role, but a par-

They are written by a team including world-renowned experts with a maximum of 50% of the writing task force representing Europe and North America and 50% or more from the rest of the world. The peer review team is also made up of worldwide experts further enriching these documents and leading to a final phase of public review open to all. The viewpoints of persons with lived experience are embedded within this global implementation guideline process including also a public review phase. In addition, we aim to update all our guideline documents as appears appropriate based on new data every 1-2 years. Through this innovative approach iCARDIO Alliance hopes to enhance guideline dissemination and implementation on a global scale.

ticularly high burden of HF exists, even after accounting for variations in age demographics,²²⁻²⁴ there remains a huge gap in reaching the guideline-recommended doses for all the medications. We lack an understanding of the reasons behind this gap in practice.^{20,21} Similarly, sub-Saharan Africa and Asia face significant challenges in HF management, with limited access to essential medications and therapies due to economic constraints, underdeveloped healthcare infrastructure, and a high prevalence of risk factors such as hypertension and rheumatic heart disease.^{1,25-27} These global disparities underscore the need for new, universally applicable guidelines that can ensure both relevance and effectiveness in HF management.

Thus, this document strives to usher in a new era of practical guidelines that are responsive to unique challenges faced by individual patients and healthcare providers during HF management. By integrating past guidelines with the latest research and evidence, it offers an updated, comprehensive approach, that equips healthcare providers with the tools needed to address the evolving challenges in diagnosis, prevention, and management of acute and chronic HF. Lastly, HF management can be overwhelming due to economic burden, particularly in resource-limited countries with restricted access to advanced therapies. To address this, we have proposed alternative treatment strategies where recommended or strongly recommended grading was given. In cases of suggestive grading, we have not provided economic considerations as these were suggestions, and may be acceptable to forego in cases of economic limitations. These considerations ensure that the guidelines remain adaptable to diverse healthcare settings while maintaining their efficacy in improving patient outcomes.

Since publication of the 2025 iCARDIO Alliance Global Implementation Guidelines on Heart Failure, new evidence has emerged that has implications for selected aspects of HF management. The 2026 update of the original 2025 of the iCARDIO Global Heart Failure guidelines²⁸ incorporates new data regarding vericiguat, cardiac glycosides, GLP-1 receptor agonist-based therapies, transthyretin cardiac amyloidosis, cardiac myosin inhibitors, and vaccination strategies. The recommendations have been revised where these data were considered

sufficient to modify clinical practice, while maintaining the implementation-focused approach of these guidelines across healthcare systems with differing resources. Please see also the dedicated document explaining in more detail the changes made in the 2026 edition of the Global Heart Failure guideline vs the 2025 edition of these guidelines.²⁹ To maintain the original numbering sequence for the recommendations, we added letters (“A” or “B” or “C”, respectively) for some new recommendations. In several cases, one previous recommendation became two new recommendations.

Grading/recommendations

Based on the available evidence and consensus among the committee members regarding the risks and benefits of interventions, the recommendations were classified as strongly recommend (SR), recommend (R), suggest (Su), and do not do (DND) (Table 1). To make the document more readable and concise, we decided to not reference each recommendation. Also, we acknowledge that there have been discussions whether to use the term “people with HF” or “patients with HF”. In this document, we will use “patients with HF” as this is more commonly used globally.

When recommendations were made, also more recent published evidence was taken into account, for instance regarding device therapies (*i.e.* on RESHAPE-HF2 and an M-TEER-meta-analysis, for MONITOR-HF, and the TRILUMI- NATE trial),^{30–36} drug therapy in HF (FAIR-HF2, a meta-analysis on intravenous iron, ATTRIBUTE-CM, HELIOS-B trial, FINEARTS-HF, 2 STEP-HFpEF trials, STEP-HFpEF meta-analysis, and the SUMMIT trial).^{37–47} On the issue of fluid restriction, we considered also the FRESH-UP trial.⁴⁸ For this 2026 update, newly available evidence informing revised recommendations includes VICTOR and pooled analyses of VICTORIA and VICTOR for vericiguat, the trial reports of DIGIT-HF and DECISION for cardiac glycosides as well as the related meta-analysis, contemporary studies of cardiac myosin inhibitors, and emerging evidence regarding preventive vaccination strategies in patients with HF.^{49–61}

Prevention of heart failure

Therapeutic interventions and lifestyle modification in patients at risk of HF have been associated with a decreased incidence of HF and the likelihood of hospitalization due to HF. Considering the available data, the following recommendations have been proposed for the prevention of HF (Figure 1, Table 2).

Diagnostics

The diagnosis of HF requires the presence of symptoms and/or signs of HF and objective evidence of cardiac dysfunction. Symptoms and signs lack sufficient accuracy to be used alone

to make the diagnosis of HF, thus under- and misdiagnosis of HF can commonly occur. To address this, diagnostic modalities should be utilized to diagnose or determine the prognosis of HF (Figure 1, Table 3).

Of note, this guideline diagnostically and therapeutically distinguishes between HFrEF and HFpEF. It is recognized that for all practical intents and purposes patients that elsewhere are considered as HF patients with “mid-range” or “mildly-reduced” LVEF (termed patients with “HFmrEF” and typically defined as patients with an LVEF of 40–49%) are considered as patients with HFrEF. It is recognized that diagnostic certainty in these patients is somewhat reduced (due to the variability of LVEF assessment) and that the absolute benefit of GDMT may be somewhat less than in patients with LVEF <40%.

For practical diagnostic and therapeutic purposes, these guidelines therefore continue to classify HF into two main groups: HFrEF, defined by LVEF <50%, and HFpEF, defined by LVEF ≥50%. Patients with LVEF between 40% and 49% do not appear to represent a distinct pathophysiological phenotype but rather occupy a continuum between traditional HFrEF and HFpEF, and several components of GDMT remain effective across the LVEF spectrum below 50%. This simplified two-category classification is intended to facilitate implementation of treatment recommendations while recognizing that comparison with trials and other guidelines using the HFmrEF category may require careful interpretation.

In addition, we define HF with improved ejection fraction (HFimpEF) as an improvement in LVEF of at least 10 percentage points to an LVEF ≥50% in a patient previously diagnosed with HFrEF.

Treatment

Drugs

Pharmacological therapies have been shown to improve symptoms, reduce hospitalizations and reduce mortality in patients with HF by improving cardiac function and slowing the disease progression. Despite strong evidence supporting the benefits of certain medications for HFrEF, several other classes of medications still have either unproven benefits or potential risks of increased fluid retention, drug interactions, HF hospitalization, or mortality. Recommendations regarding the pharmacological therapies for patients with HF are summarized in Figure 2 and Figure 3 as well as in Table 4 focusing on drugs commercially available in major parts of the world.

Vericiguat

The VICTOR trial evaluated vericiguat in a more stable ambulatory population of patients with HFrEF (LVEF ≤40%) and NT-proBNP concentrations up to 6,000 pg/mL. Although VICTOR did not significantly reduce the primary composite endpoint of cardiovascular death or first HF hospitalization, cardiovascular mortality was reduced by 17%. A subsequent pooled par-

ticipant-level analysis of VICTORIA and VICTOR, including more than 11,000 patients, demonstrated a modest reduction in cardiovascular death or HF hospitalization and supported benefit across a broader range of NT-proBNP concentrations. These findings support increasing the NT-proBNP threshold in Recommendation 4-17 from <5,000 pg/mL to <6,000 pg/mL.

Cardiac glycosides

Recent randomized data have renewed interest in low-dose cardiac glycosides as adjunctive therapy in selected patients with HFrEF who remain symptomatic despite contemporary GDMT. In DIGIT-HF, low-dose digitoxin reduced the composite of all-cause death or first HF hospitalization for worsening HF compared with placebo. In DECISION, digoxin did not significantly reduce the primary composite of worsening HF events or cardiovascular mortality, but reduced worsening HF events and was generally well tolerated when serum digoxin concentrations were maintained at low serum digoxin concentrations between 0.5 and 0.9 ng/mL.

Digoxin and digitoxin have similar therapeutic effects but differ pharmacokinetically. Appropriate clinical follow-up and therapeutic drug monitoring are important because of the narrow therapeutic window. Plasma digoxin or digitoxin concentrations should therefore be assessed after initiation or dose adjustment when feasible, particularly in patients at increased risk of toxicity, including those with low body weight or impaired kidney function. Their low cost and widespread availability may make cardiac glycosides particularly useful as adjunctive therapy in selected patients in resource-limited healthcare settings.

Heart failure with improved ejection fraction

Patients with HFimpEF, defined as an improvement in LVEF of at least 10 percentage points to $\geq 50\%$ in a patient previously diagnosed with HFrEF, should generally continue GDMT for HFrEF despite recovery of LVEF. Improvement in LVEF does not necessarily indicate resolution of the underlying disease process, and withdrawal of therapy may be associated with relapse of HF and LV dysfunction.

GLP-1 receptor agonist-based therapies

Semaglutide and tirzepatide have demonstrated substantial weight loss and clinically important improvements in symptoms and health status in patients with obesity and HFpEF. Favorable reductions in HF events were also observed in the STEP-HFpEF and SUMMIT trial programs; however, fewer than 100 clinical events occurred in each program, limiting certainty regarding their effects on clinical outcomes. In addition, further long-term safety data in patients with HF are needed. Compared with the 2025 iCARTIO Alliance guideline, Recommendation 4-24 for GLP-1 receptor agonist-based therapy in patients with obesity and HFpEF has been downgraded from strongly recommend recommending. The current recommen-

dation is based primarily on the benefits for weight loss, symptoms, exercise capacity and to some degree quality of life, while additional large event-driven trials are required to establish the effects of these therapies on HF hospitalization and other clinical outcomes.

Devices

A crucial role has been played by RCTs in shaping decisions regarding cardiac implantable devices such as implantable cardioverter-defibrillators (ICDs), and cardiac resynchronization therapy (CRT) over the past two decades. While subgroup analyses of these trials have provided additional insights, it is important to note that they were not the primary endpoints of these studies and should be interpreted cautiously. Recently, cardiac contractility modulation (CCM) and baroreflex activation therapy (BAT) have shown beneficial effects in patients with HF. Strategies and recommendations regarding device therapies are summarized in Table 5 and Figure 2.

Surgery and trans-catheter procedures

Strategies for invasive management and device-based therapies for patients with severe valvular diseases or coronary artery diseases are mentioned in Table 6 and Figure 2.

Special consideration

Heart failure management becomes more challenging in the presence of various comorbidities, such as amyloidosis. Moreover, in pregnancy, certain medications should be avoided due to potential risks to the fetus and other adverse effects. Recommendations about the management of HF in such special conditions are highlighted in Table 7 and Table 8, and Figure 4.

Transthyretin cardiac amyloidosis

Disease-modifying therapies for transthyretin cardiac amyloidosis include TTR stabilization with tafamidis or acoramidis and TTR silencing with vutrisiran. No head-to-head comparisons between these therapies have been conducted, and it is therefore not possible to establish clinically meaningful differences in efficacy between individual agents. Furthermore, although pharmacological differences exist among the available agents, the clinical significance of these differences remains uncertain.

Cardiac myosin inhibitors

Recent randomized evidence has strengthened the role of cardiac myosin inhibitors in symptomatic obstructive hypertrophic cardiomyopathy. In MAPLE-HCM, aficamten was superior to metoprolol monotherapy in improving exercise capacity and also improved symptoms, quality of life, LV outflow tract gradients, and NT-proBNP. These data support upgrading the recom-

mendation for cardiac myosin inhibitors in symptomatic obstructive HCM from recommend to strongly recommend. Emerging data with aficamten in symptomatic non-obstructive HCM also suggest improvements in symptoms and exercise capacity, although the evidence in this population remains less established and warrants more cautious interpretation.

Vaccinations

Patients with HF are particularly vulnerable to decompensation and adverse cardiovascular outcomes following respiratory infections. The updated recommendations therefore provide more specific guidance regarding preventive vaccination rather than combining influenza and pneumococcal vaccination within a single recommendation.

Implementation for the future

HF classification and clinical trial design should increasingly reflect the biological continuum of ventricular function rather than historical trial-defined LVEF categories. For implementation purposes, these guidelines favor two principal groups: HFrEF with LVEF <50% and HFpEF with LVEF ≥50%. Patients with LVEF 41–49% should generally be considered within the HFrEF population unless there is a specific scientific rationale to distinguish them. Future HF trials should consider either this simplified two-group classification or enrollment across the entire LVEF spectrum with treatment effects assessed continuously (Table 9).

Conclusions

The recommendations provided in this document offer a comprehensive framework for HF management, drawing on the most recent evidence to support physicians in their practice. However, it is pertinent to note that they should not replace clinical judgment. Effective HF management requires adapting these guidelines to the unique circumstances of each patient and the resources available in their region. A comprehensive overview of the recommendations for management of patients with HFpEF and HFrEF is given in Figures 5 and 6. It is crucial for healthcare providers to offer personalized care tailored to each patient's specific clinical profile, symptoms, comorbidities, and individual preferences. Recognizing potential obstacles to implementing these recommendations, including resource constraints, access to particular interventions and technologies, cultural influences and local standards of care is essential for effective application of these guidelines. By integrating these recommendations with individualized patient care and addressing local healthcare dynamics, clinicians can optimize HF management and improve quality of life for patients. The 2026 update incorporates important new evidence regarding HF classification, vericiguat, cardiac glycosides, GLP-1 receptor agonist-based therapies, transthyretin cardiac amyloidosis, cardiac myosin inhibitors, and preventive vaccination strategies. These updates reinforce the need to integrate emerging evidence with individualized care, continued GDMT where appropriate, and consideration of resource availability across different healthcare systems.

Table 1. Grading and recommendations.

No.	Definition	Level of Recommendation
1-01	Evidence or consensus that a specific diagnostic test or treatment is effective, beneficial and valuable.	Strongly recommend (SR)
1-02	Majority of evidence or opinions support the benefits or effectiveness.	Recommend (R)
1-03	Usefulness or effectiveness is less clearly supported by evidence or opinion.	Suggest (Su)
1-04	Evidence or consensus suggests that it is ineffective and, in some cases, may even be harmful.	Do not do (DND)

Table 2. Recommendations for the prevention of heart failure.

No.	Guideline Statement	Level of Recommendation
2-01	Counsel against sedentary habits, tobacco, and alcohol abuse to decrease the risk of HF.	SR
2-02	Request genetic counseling and testing (if available) to facilitate early diagnosis and prevent or delay the progression of disease in family members of patients with non-ischemic cardiomyopathy.	R
2-03	Treat hypertension to recommended blood pressure targets to prevent subsequent HF.	SR
2-04	Use evidence-based SGLT2 inhibitors to reduce HF hospitalizations in patients with T2DM or CKD regardless of glycemic status.	SR
<i>Resources severely limited</i>	<i>Use empagliflozin, dapagliflozin or any regionally approved SGLT2 inhibitor to reduce HF hospitalization in patients with T2DM or CKD regardless of glycemic status.</i>	
2-05	Use evidence-based GLP-1 RA based therapies to reduce HF hospitalizations in patients with T2DM and obesity.	R
2-06	Use evidence-based SGLT2 inhibitors to reduce HF hospitalization in post-AMI patients with LVEF $\leq 45\%$ and/or pulmonary congestion.	Su
2-07	Use finerenone in patients with T2DM and CKD to reduce the risk of HF hospitalization.	SR
<i>Resources severely limited</i>	<i>Use any MRA in patients with T2DM and CKD to reduce the risk of HF hospitalization.</i>	

To be continued on next page

No.	Guideline Statement	Level of Recommendation
2-08	Use optimal therapies (i.e. statins, antihypertensives) in patients with CVD to prevent or delay the onset of HF and reduce the risk of HF hospitalization.	SR
2-09	Use ACEi (or ARB if intolerant to ACEi) in patients with/without MI and LVEF $\leq 40\%$ to decrease the risk of symptomatic HF and mortality.	SR
2-10	Use HF-specific beta-blockers in patients with prior MI/ACS and LVEF $\leq 40\%$, to decrease the risk of HF.	SR
2-11	Use HF-specific beta-blockers in patients with LVEF $\leq 40\%$ and no prior MI or ACS, to decrease the risk of symptomatic HF and mortality.	SR
2-12	Advise at least 5% weight loss in patients with severe obesity (BMI ≥ 35 kg/m ²) to decrease the risk of HF.	R
2-13	Use appropriate antibiotics in patients with Group A beta hemolytic streptococcal infection for primary and secondary prevention of RF and RHD, especially in LMIC.	R

SR, strongly recommend; R, recommend; Su, suggest; DND, do not do; ACEi, angiotensin-converting enzyme inhibitors; ACS, acute coronary syndrome; AMI, acute myocardial infarction; ARB, angiotensin receptor blocker; BMI, body-mass index; CVD, cardiovascular disease; CKD, chronic kidney disease; GDMT, guideline-directed medical therapy; GLP-1RA, glucagon-like peptide 1 receptor agonist; HF, heart failure; LMIC, low- and middle- income countries; LVEF, left ventricular ejection fraction; MI, myocardial infarction; MRA, mineralocorticoid receptor antagonist; RHD, rheumatic heart disease; RF, rheumatic fever; SGLT2, sodium-glucose cotransporter-2; T2DM, type 2 diabetes mellitus.

Table 3. Recommendations for the diagnostic tests in patients with heart failure.

No.	Guideline Statement	Level of Recommendation
3-01	Inquire regarding family history, previous malignancy, acromegaly, hypo- or hyperthyroidism, exposure to metals or chemicals, alcohol, illicit drug use and exposure to HIV, chemotherapy, immunotherapy or cardiac irradiation in patients with suspected cardiomyopathy.	SR
3-02	Perform EKG and chest X-ray on all patients with suspected HF.	SR
3-03	Measure BNP or NT-proBNP or MR-proANP, where available, to make or exclude new diagnosis of HF in patients presenting with dyspnea. The best use for natriuretic peptides is to rule-out presence of heart failure.*	SR
<i>Resources severely limited</i>	<i>When use of natriuretic peptides is not covered or reimbursed, consider echocardiography and/or chest X-ray to aid diagnosis of HF and treatment decisions.</i>	
3-04	Perform serological tests to diagnose Chagas disease in patients with suspected HF, specifically in endemic areas such as Latin America.	R

To be continued on next page

No.	Guideline Statement	Level of Recommendation
3-05	Perform TTE during the initial assessment (recommendation a), and 3-6 months after optimization of therapies for patients with HFrEF (b); to evaluate cardiac structure and function, and to guide management.	(a): SR
		(b): R
<i>Resources somewhat limited</i>	<i>Perform TTE during the initial assessment and diagnosis and then subsequently, only if there are significant changes to the patient's clinical status.</i>	
3-06	Perform CMR, where available/affordable, to evaluate myocardium in possible cases of inflammatory diseases like myocarditis or sarcoidosis, infiltrative diseases like amyloidosis or Fabry's disease, or iron overload/hemochromatosis, hypertrophic cardiomyopathy, and suspected previous infarction.	R
<i>Resources somewhat limited</i>	<i>Consider CMR focusing on patients where the diagnosis remains uncertain following initial clinical evaluation and patient's clinical status changes significantly despite being on GDMT to rule out infiltrative diseases.</i>	
3-07	Perform PET/CT scan in patients with suspected sarcoidosis.	R
3-08	Perform point of care ultrasound in patients with HF to monitor congestion.	R
3-09	Perform DPD/PYP/HMDP scintigraphy in patients with suspected TTR amyloidosis.	SR
3-10	Evaluate patients with HF for possible ischemic heart disease etiology to identify the cause of HF and assess the anatomy and functional status. The choice of evaluation method should depend on pre-test probability, availability of the diagnostic modality, and local expertise.	SR
3-11	Perform invasive hemodynamic monitoring to guide the management of selected patients with HF and persistent or worsening NYHA class III/IV symptoms, signs, or diagnostic parameters when hemodynamic status is uncertain.	Su
3-12	Perform endomyocardial biopsy in patients with HF, if a specific diagnosis is suspected that could affect the management and prognosis.	Su
3-13	Perform non-invasive home tele-monitoring in patients with HF, to decrease hospitalization for HF and risk of CV death.	Su
3-14	Perform CPET for selected patients with HF to help determine the cause and severity of exercise intolerance and eligibility for advanced therapies such as MCS and heart transplant.	R

To be continued on next page

No.	Guideline Statement	Level of Recommendation
<i>Resources severely limited</i>	<i>When resources are limited, the 6MWT can help determine the need for referral for advanced therapies such as MCS and heart transplant.</i>	
3-15	Perform RHC in patients with persistent right-sided HF to determine PAPI, PASP, PVR, transpulmonary gradient, PCWP, RVSWI and to exclude left-sided HF as underlying cause.	R
3-16	Consider genetic counselling and testing in patients with suspected non-ischemic cardiomyopathy and relevant family history or cardiomyopathy with arrhythmias.	Su
<i>Resources somewhat limited</i>	<i>Patients who have presentation or family history suggestive of genetic dilated cardiomyopathy but lack either the access or interest for genetic testing should nonetheless be counseled about screening family members with EKG and echocardiography</i>	
3-17	Perform a formal sleep study to determine the presence of CSA in patients being considered for positive pressure mask therapy of sleep apnea with HF.	Su

SR, strongly recommend; R, Recommend; Su, suggest; DND, do not do; 6MWT, 6-minute walk test; BNP, B-type natriuretic peptide; CMR, cardiac magnetic resonance; CSA, central sleep apnea; CPET, cardiopulmonary exercise testing; CV, cardiovascular; DPD, 3,3-diphosphono-1,2-propanodicarboxylic acid; GDMT, guideline-directed medical therapy; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; HMDP, hydroxymethylene diphosphonate; MCS, mechanical circulatory support; NT-proBNP, N-terminal prohormone of B-type natriuretic peptide; NYHA, New York Heart Association; PAPI, pulmonary artery pulsatility index; PASP, pulmonary artery systolic pressure; PCWP, pulmonary capillary wedge pressure; PET, positron emission tomography; PVR, pulmonary vascular resistance; PYP, pyrophosphate; TTE, transthoracic echocardiography; RHC, right heart catheterization; RVSWI, right ventricular stroke work index.

*Note: Best cut-offs to rule-out heart failure in the chronic setting using natriuretic peptides are for BNP: <35 pg/mL, for NT-proBNP: <125 pg/mL, and for MR-proANP: <120 pmol/L.

Table 4. Recommendations for pharmacological therapies in patients with heart failure.

No.	Guideline Statement	Level of Recommendation
4-01	Use diuretics in patients with HF and signs and symptoms of congestion to alleviate symptoms, improve functional status and decrease the risk of HF hospitalization, irrespective of LVEF.	SR
4-02	Use higher dose of IV loop diuretics or addition of a second diuretic (thiazide, metolazone or acetazolamide) in patients hospitalized/non-hospitalized with HF when diuresis is inadequate to relieve signs and symptoms of congestion.	R
4-03	Among RAASi, use ARNI as first-line therapy in ambulatory patients with HFrEF to reduce mortality and morbidity. If ARNI is contraindicated, use ACEi or ARB.	SR
4-04	In patients with HFrEF and NYHA II and III class symptoms who can tolerate ACEi or ARB, use ARNI as a replacement therapy to reduce mortality and morbidity.	SR
<i>Resources severely limited</i>	<i>Any ACEi or ARB can be used instead of ARNI among patients with HFrEF and NYHA II and III class symptoms to reduce mortality and morbidity.</i>	
4-05	Do not use ARNI simultaneously with ACEi or within 36 hours of the last ACEi dose.	DND
4-06	Do not use ARNI or ACEi in patients with a history of angioedema.	DND
4-07	Use bisoprolol, carvedilol, nebivolol, or sustained-release metoprolol succinate in patients with HFrEF to reduce the risk of cardiovascular mortality and HF hospitalization.	SR
4-08	Use MRA in patients with HFrEF, eGFR>30 mL/min/1.73m ² and potassium <5.0 mEq/L, to reduce morbidity and mortality.	SR
4-09	Do not use MRA in patients whose potassium cannot be maintained <5.5 mEq/L while on MRA, to prevent hyperkalemia-related adverse events.	DND
4-10	Use potassium binders (patiomer, sodium zirconium cyclosilicate) in patients with HF and hyperkalemia (>5.5mEq/L) who are unable to tolerate any dose of RAASi, (a) to enable at least one RAASi initiation, and (b) MRA dose-up titration.	(a): R
		(b): Su
4-11	Use eplerenone (regardless of LVEF) or finerenone (in HFpEF) among patients who develop gynecomastia on spironolactone.	SR
<i>Resources somewhat limited</i>	<i>Use eplerenone in patients who develop gynecomastia on spironolactone.</i>	

To be continued on next page

No.	Guideline Statement	Level of Recommendation
4-12	Use evidence based SGLT2 inhibitors in patients with HF regardless of LVEF, to reduce the risk of HF hospitalization and CV death.	SR
4-13	Optimize GDMT and attempt to achieve target doses to ensure maximum therapeutic benefits and improved patients' outcomes.	SR
<i>Resources somewhat or severely limited</i>	<i>Advocate for the use of affordable, generic medications and explore strategies to overcome barriers to drug access in resource-limited settings.</i>	
4-14	Use a combination of hydralazine and isosorbide dinitrate in Black patients with NYHA class III-IV symptoms, despite receiving optimal therapy, to improve QoL and decrease morbidity and mortality.	Su
4-15	Use ivabradine in patients with HFrEF (LVEF $\leq 35\%$), NYHA class II-IV symptoms, and sinus rhythm with a heart rate ≥ 70 bpm despite being on maximally tolerated GDMT, including beta-blockers, to reduce the risk of HF hospitalization and CV death.	R
4-16	Use oral soluble guanylate cyclase stimulator (vericiguat) to reduce HF hospitalization and CV death in high-risk patients with symptomatic HFrEF despite GDMT.	Su
4-17	Use oral soluble guanylate cyclase stimulator (vericiguat) to reduce HF hospitalization and CV death in high-risk patients with symptomatic HFrEF despite GDMT who have a NT-proBNP $< 6,000$ pg/mL.	R
4-18	Do not use soluble guanylate cyclase stimulator (vericiguat) simultaneously with PDE5 inhibitors.	DND
4-19A	Use digoxin (target serum concentration 0.5-0.9 ng/mL) or digitoxin (target serum concentrations 8-18 ng/mL) in patients with HFrEF who remain symptomatic despite GDMT to decrease worsening HF events and HF hospitalization.	R
4-19B	If feasible, perform a plasma digitoxin / digoxin level assessment approximately 4–6 weeks after initiation or dose adjustment, while recognizing that earlier assessment may be appropriate when clinically indicated, to guide therapy and reduce the risk of toxicity. Particularly this should be considered for patients with low BMI and CKD.	R
<i>Resources somewhat limited</i>	<i>Consider digitoxin (if available) rather than digoxin when therapeutic drug monitoring and clinical follow-up have low availability, as plasma level assessment and dose adjustment may be required less often.</i>	

To be continued on next page

No.	Guideline Statement	Level of Recommendation
4-19C	Do not initiate digoxin therapy in patients with severe renal insufficiency (eGFR <30mL/min/1.73m ²) in settings where both reliable clinical follow-up and therapeutic drug monitoring cannot be ensured. <u>Note:</u> At least one of the following should be available: reliable clinical follow-up or therapeutic drug monitoring.	DND
4-20	Patients with HF with improved ejection fraction (HFimpEF), defined as an improvement in LVEF of at least 10 percentage points to ≥50%, should generally continue GDMT for HFrEF despite improvement of LVEF.	SR
4-21	Use MRAs in patients with HFpEF to decrease HF hospitalization. (a) finerenone; (b) spironolactone	(a): R
		(b): Su
<i>Resources severely limited</i>	<i>Use spironolactone in patients with HFpEF to decrease HF hospitalization.</i>	
4-22	Use ACEi or ARB in patients with HFpEF, especially those at the lower end of the LVEF spectrum to reduce the risk of HF hospitalization.	Su
4-23	Use ARNI in patients with HFpEF, especially those at the lower end of the LVEF spectrum. Particularly consider use in patients with LVEF <58% and in women.	R
4-24	Use GLP-1RA-based therapies (tirzepatide or semaglutide) in patients with obesity (BMI ≥30 kg/m ²) and HFpEF to achieve weight loss and to improve symptoms and QoL.	R
4-25	Use GLP-1RA-based therapies (tirzepatide or semaglutide) in patients with obesity (BMI ≥30 kg/m ²) and HFpEF to reduce the risk of HF hospitalization.	Su
4-26	Use IV nitroglycerin or nitroprusside as an adjuvant therapy to diuretics in patients admitted with decompensated HF or pulmonary congestion, in the absence of systemic hypotension (SBP<90mmHg), to relieve dyspnea.	Su
4-27	Reduce digoxin dose or possibly discontinue in patients with acute renal injury or patients with severe renal insufficiency (eGFR<30 mL/min/1.73m ²), to prevent adverse events.	SR
4-28	Use intravenous iron supplementation with ferric carboxymaltose or ferric derisomaltose to improve symptoms, and exercise capacity in patients with HFrEF and iron deficiency with or without anemia.	SR
4-29	Use intravenous iron supplementation with ferric carboxymaltose or ferric derisomaltose to reduce the risk of HF hospitalization and CV death in patients with HFrEF and iron deficiency with or without anemia.	R

To be continued on next page

No.	Guideline Statement	Level of Recommendation
<i>Resources somewhat limited</i>	<i>Use iron sucrose, ferric carboxymaltose or ferric derisomaltose (whichever is affordable) instead of the above.</i>	
<i>Resources severely limited</i>	<i>Use of any non-dextran containing intravenous iron supplementation may be considered, whichever is accessible.</i>	
4-30	Initiate all 4 foundational therapies (ARNI, SGLT2 inhibitors, beta-blockers and MRA) in patients with HFrEF, at low doses once hemodynamically stabilized and then optimize dosages every 1-2 weeks, depending on symptoms, vitals and labs, and then at 3-4 months follow-up.	R
<i>Resources somewhat limited</i>	<i>Initiate the least expensive combination of quadruple therapy in patients with HFrEF, at low doses once hemodynamically stabilized and then optimize dosages every 1-2 weeks, depending on symptoms, vitals and labs, and then at 3-4 months follow-up.</i>	
<i>Resources severely limited</i>	<i>Use foundational triple therapy (ACEi/ARB, beta-blockers and MRA) at optimized doses and diuretics as needed.</i>	
4-31	Refer patients with HF to cardiac rehabilitation program (for tailored exercises at least 30 minutes 3 times per week for 30 days) to improve symptoms and QoL.	R
4-32	Do not use thiazolidinediones and non-dihydropyridine calcium channel blockers in patients with HF and LVEF <50%, as they increase the risk of volume overload.	DND
4-33	Do not use DPP-4 inhibitors (saxagliptin and alogliptin) in patients with HF, T2DM and high CVD risk, as they increase this risk of HF hospitalization.	DND
4-34	Do not use NSAIDs or COX-2 inhibitors in patients with HF, as they increase the risk of worsening HF and HF hospitalization.	DND
4-35	Use GDMT before discharge in patients hospitalized with HF to improve outcomes and reduce HF hospitalization.	SR
4-36	Continue and optimize pre-existing GDMT in patients hospitalized with HFrEF (with no absolute contraindication) to improve outcomes.	SR
4-37	Do not routinely discontinue diuretics and other GDMT in patients experiencing mild decline in eGFR or asymptomatic reduction in blood pressure during HF hospitalization.	SR

To be continued on next page

No.	Guideline Statement	Level of Recommendation
4-38	Consider continuous IV inotropic therapy as "bridge therapy" for patients with advanced HF refractory to GDMT who are eligible and awaiting MCS or cardiac transplantation.	Su
4-39	Consider continuous intravenous inotropic therapy as palliative care for patients with advanced HF who are refractory to GDMT and device therapy and ineligible for MCS or heart transplantation.	Su

SR, strongly recommend; R, recommend; Su, suggest; DND, do not do; ACEi, angiotensin converting enzyme inhibitors; ACS, acute coronary syndrome; AMI, acute myocardial infarction; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitors; BPM, beats per minute; BNP, B-type natriuretic peptide; COX-2, cyclo-oxygenase-2; CV, cardiovascular; CVD, cardiovascular disease; DPP-4, dipeptidyl peptidase-4; eGFR, estimated glomerular filtration rate; GDMT, guideline-directed medical therapy; GLP-1RA, glucagon-like peptide 1 receptor agonist; HF, heart failure; HFimpEF, heart failure with improved ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; IV, intravenous; LVAD, left ventricular assist device; LVEF, left ventricular ejection fraction; MCS, mechanical circulatory support; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal prohormone of B-type natriuretic peptide; NSAIDs, non-steroidal anti-inflammatory drugs; NYHA, New York Heart Association; PDE5, phosphodiesterase-5; QoL, quality of life; RAASi, Renin-angiotensin-aldosterone system inhibitors; SGLT2, sodium-glucose cotransporter-2; SP, systolic blood pressure; T2DM, type 2 diabetes mellitus, and TSAT, transferrin saturation. In patients with LVEF 40-49%, diagnostic accuracy of test is less certain (due to the variability of LVEF assessments) and the absolute amount of therapeutic benefit of GDMT is somewhat less than in patients with LVEF <40%.

Table 5. Recommendations for the device therapies in patients with heart failure.

No.	Guideline Statement	Level of Recommendation
5-01	Evaluation for ICD candidacy for primary prevention of SCD in patients with HFrEF must not be made for at least 3 months of maximally tolerated quadruple GDMT as the LVEF improves in significant portion of patients thereby decreasing the need for ICD.	SR
5-02	Consider ICD therapy to decrease the risk of SCD and mortality in patients with a) ischemic, and b) non-ischemic HFrEF; LVEF ≤35%; NYHA II or III symptoms on chronic GDMT and prognosis >1 year survival.	(a): SR
		(b): R
<i>Resources severely limited</i>	<i>Restrict use of ICD therapy to reduce the risk of SCD and total mortality in patients with ischemic/non-ischemic HFrEF; LVEF ≤35%; NYHA II or III symptoms on chronic GDMT, survival >1 year among patients who are at highest risk (e.g. arrhythmogenic cardiomyopathy) and most likely to benefit such as those with NYHA Class II symptoms, severely reduced LVEF and frequent NSVT, and who have low likelihood for reverse remodeling.</i>	

To be continued on next page

No.	Guideline Statement	Level of Recommendation
5-03	Use ICD therapy to decrease the risk of SCD and overall mortality in patients who are at least 40 days post-MI, have an LVEF $\leq 30\%$, and have a prognosis of >1 year survival.	SR
<i>Resources severely limited</i>	<i>Optimize GDMT before considering ICD, in patients who are at least 40 days post-MI, have an LVEF $\leq 30\%$, and have a prognosis of >1 year survival.</i>	
5-04	Use a wearable ICD for a limited period or as a bridge to an implanted device in patients with HF who are at high risk of SCD.	Su
5-05	Do not use ICD therapy in patients with NYHA class IV and severe symptoms unresponsive to medical therapy, unless they are eligible for CRT, a VAD, or cardiac transplantation.	DND
5-06	Use ICD in patients with genetic arrhythmogenic cardiomyopathy and LVEF $<45\%$ to decrease the risk of sudden death.	Su
5-07	Use CRT to reduce mortality, and HF hospitalization and improve symptoms and QOL in ambulatory patients with LVEF $\leq 35\%$; SR; LBBB with QRS ≥ 150 ms; NYHA II-IV symptoms on maximally tolerated GDMT for at least 3 months.	SR
<i>Resources severely limited</i>	<i>Optimize GDMT maximally in patients with LVEF $\leq 35\%$; SR; LBBB with QRS ≥ 150ms; NYHA II-IV symptoms on GDMT, and then consider the least expensive available CRT/LBBB pacing device, whenever appropriate and consider recycling of cardiac implantable devices.</i>	
5-08	Use CRT to reduce mortality and HF hospitalization, as well as to improve symptoms and QOL in patients with LVEF $\leq 35\%$; SR; non-LBBB pattern with QRS ≥ 150 ms; and NYHA II-IV symptoms on maximally tolerated GDMT for at least 3 months.	R
5-09	Use CRT to reduce mortality and HF hospitalization, as well as improve symptoms and QOL in patients with high-degree or complete atrioventricular block and LVEF $<50\%$.	Su
5-10	Use CRT to reduce mortality and HF hospitalization, as well as improve symptoms and QOL, for patients with LVEF $\leq 35\%$, SR, LBBB with a QRS duration of 130-149 ms, and NYHA class II-IV symptoms on maximally tolerated GDMT for at least 3 months.	Su
5-11	Use CRT in patients with LVEF $\leq 35\%$ and have pre-existing RV pacing with symptoms of HF to reduce morbidity.	R

To be continued on next page

No.	Guideline Statement	Level of Recommendation
5-12	Use CRT to improve symptoms and QoL and reduce mortality and HF hospitalization in patients with AF and LVEF $\leq 35\%$ on GDMT if: a) they need RV pacing of more than 20% or otherwise qualify for CRT, or b) AV nodal ablation or pharmacologic control will enable approximately 100% ventricular pacing with CRT.	R
5-13	Use CCM with the Optimizer Smart system to improve symptoms, QOL and exercise tolerance in patients with HF with LVEF 25-45% on GDMT not suitable for CRT.	R
5-14	Use baroreflex stimulation with the Barostim Neo System to improve symptoms, QOL and exercise tolerance in patients with HF and LVEF $\leq 35\%$ on GDMT.	Su
5-15	Use phrenic nerve stimulation with the Remedē System to improve symptoms, sleep quality and QOL in adult patients (including those with HF) with central sleep apnea.	Su
5-16	Implant durable LVAD in patients with advanced HFrEF with NYHA class IV symptoms who are deemed to be dependent on continuous IV inotropes or temporary MCS or are either already taking or are intolerant to GDMT.	SR
5-17	Use long-term MCS in patients with advanced HFrEF who have NYHA class IV symptoms despite GDMT and not eligible for cardiac transplantation.	R
5-18	Use temporary MCS, including percutaneous and extracorporeal ventricular assist devices, as a bridge to recovery or a bridge to decision in patients with advanced HFrEF and hemodynamic compromise and shock.	Su
5-19	Use long-term MCS in patients with HFrEF refractory to medical and device therapy and waiting for cardiac transplantation, as a bridge to cardiac transplantation to improve symptoms.	R
5-20	Use remote system HF monitoring/telemedicine devices to guide HF management.	R
5-21	Use CardioMems in eligible patients on GDMT to reduce the risk of HF hospitalization.	R

SR, strongly recommend; R, recommend; Su, suggest; DND, do not do; AV, atrioventricular; BAT, baroreflex activation therapy; CCM, cardiac contractility modulation; CRT, cardiac resynchronization therapy; GDMT, guideline-directed medical therapy; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; HCM, hypertrophic cardiomyopathy; ICD, implantable cardioverter-defibrillator; IV, intravenous; LAP, left atrial pressure; LBBB, left bundle branch block; LVAD, left ventricular assist device; LVEF, left ventricular ejection fraction; MCS, mechanical circulatory support; MI, myocardial infarction; NSVT, non-sustained ventricular tachycardia; NYHA, New York Heart Association; QoL, quality of life; SCD, sudden cardiac death; SR, sinus rhythm; VAD, ventricular assist device.

Table 6. Recommendations for the invasive management in patients with heart failure.

No.	Guideline Statement	Level of Recommendation
6-01	Perform surgical revascularization (CABG) plus GDMT in selected patients with HFrEF (LVEF $\leq 35\%$) and suitable coronary anatomy; and if they have multivessel disease, to improve symptoms, and reduce hospitalizations, and long-term all-cause mortality.	R
6-02	Optimize GDMT and device (CRT in LBBB patients) before intervention in patients with severe secondary MR and symptomatic HFrEF, to improve MR associated LV dysfunction, as it might decrease the need for intervention.	R
6-03	Perform M-TEER to improve symptoms and reduce HF hospitalization in patients with NYHA class II-IV symptoms, severe (4+) functional MR, suitable anatomy, LVEF of 20-50%, LVESD < 70 mm, PASP < 70 mmHg, and who are not eligible for surgery and do not require coronary revascularization.	SR
<i>Resources somewhat limited</i>	<i>Instead of M-TEER, consider (a) Carillon device, (b) use rigorous GDMT and/or (c) reassess surgical alternatives.</i>	(a): R
		(b): R
		(c): Su
6-04	Perform M-TEER to improve symptoms and reduce HF hospitalization in patients with NYHA class II-IV symptoms, moderate (3+) functional MR, suitable anatomy and LVEF 20-50%.	Su
6-05	Perform mitral valve surgery in patients with secondary MR on GDMT, who are already undergoing CABG to improve symptoms.	Su
6-06	Use transcatheter indirect annuloplasty (Carillon device) in patients with moderate or higher functional MR when M-TEER seems not appropriate or feasible to improve symptoms.	Su
6-07	Use medical therapy (diuretics, neurohormonal antagonists) in patients with HF and TR to reduce symptoms and severity.	R
6-08	Perform TEER in selected patients with TR to improve QoL and reduce HF hospitalization.	R
6-09	Perform tricuspid valve surgery in patients with severe TR to reduce symptoms.	Su
6-10	Perform TAVI or SAVR in patients with HF and severe AS to improve functional symptoms and decrease the risk of mortality.	SR
6-11	Use medical therapy (RAAS inhibitors) in patients with HF symptoms and severe AR to improve symptoms.	R
6-12	Perform aortic valve surgery in patients with HF and severe aortic regurgitation regardless of LVEF to reduce mortality and improve symptoms.	SR

To be continued on next page

No.	Guideline Statement	Level of Recommendation
6-13	Perform heart transplantation for patients with advanced HF that is unresponsive to medical or device therapy (with no absolute contraindications), to improve survival and QoL.	SR

SR, strongly recommend; R, recommend; Su, suggest; DND, do not do; AF, atrial fibrillation; AS, aortic stenosis; AR, aortic regurgitation; CABG, coronary artery bypass grafting; GDMT, guideline-directed medical therapy; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; MR, mitral regurgitation; M-TEER, mitral transcatheter edge-to-edge repair; NYHA, New York Heart Association; PASP, pulmonary artery systolic pressure; QoL, quality of life; RAAS, Renin-angiotensin-aldosterone system; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation; TEER, transcatheter edge-to-edge repair; TR, tricuspid regurgitation.

Table 7. Recommendations for the special conditions in patients with heart failure.

No.	Guideline Statement	Level of Recommendation
	Cardiac amyloidosis	
7-01	Use serum and urine immunofixation electrophoresis and serum free light chains in patients with increased pre-test likelihood of cardiac amyloidosis for screening.	SR
7-02	Use bone scintigraphy to confirm TTR amyloidosis in patients with clinical suspicion of amyloidosis without evidence of serum or urine monoclonal light chains.	SR
7-03	Perform genetic testing for TTR gene sequencing, in patients with diagnosis of TTR cardiac amyloidosis, to differentiate hereditary from wild-type amyloidosis.	SR
<i>Resources severely limited</i>	<i>Strain echocardiogram could be used to diagnose cardiac amyloidosis in resource limited countries.</i>	
7-04	Use a TTR tetramer stabilizer (tafamidis, acoramidis) or TTR silencer (vutrisiran) to improve symptoms, and reduce cardiovascular death and HF hospitalizations in patients with wild-type or hereditary TTR cardiac amyloidosis and NYHA class I to III symptoms.	SR
<i>Resources severely limited</i>	<i>Diflunisal, an alternative TTR stabilizer, is recommended when newer agents are cost prohibitive to relieve symptoms and improve mortality in patients with wild or variant type cardiac amyloidosis and NYHA class I to III HF symptoms.</i>	

To be continued on next page

No.	Guideline Statement	Level of Recommendation
7-05	Use hepatic TTR production inhibitor (vutrisiran) in patients with wild or variant type TTR cardiac amyloidosis and NYHA class I to III symptoms to improve symptoms, and reduce cardiovascular death and HF hospitalizations	SR
7-06	Use anticoagulation to prevent stroke in patients with cardiac amyloidosis and AF, regardless of CHA ₂ DS ₂ -VA score.	R
7-07	Refer to multidisciplinary team and/or referral to neurology due to systemic nature of TTR amyloidosis and need for specific therapies.	R
Hypertrophic cardiomyopathy		
7-08	Use cardiac myosin inhibitors (mavacamten/aficamten) in patients with symptomatic obstructive HCM as an adjunct or alternative to beta-blockers or non-dihydropyridine calcium channel blockers to improve QoL and decrease the need for septal reduction therapies.	SR
7-08A	Use aficamten in selected patients with symptomatic non-obstructive HCM to improve symptoms, exercise capacity, and quality of life.	Su
7-09	Perform invasive therapies (septal reduction therapies) in patients with LVOT ≥ 50 mmHg (at rest or with provocation), and who are moderate to severely symptomatic despite optimal medical therapy to improve symptoms and QoL.	R
7-10	Do not use arterial and venous dilators (nitrates and PDE5 inhibitors), and digoxin in patients with HCM and LVOTO.	DND
7-11	Implantation of ICD for primary prevention of sudden cardiac death should be guided by family history of sudden death and other high risk factors as included in the specific HCM risk scores.	R
7-12	Use anticoagulation to prevent stroke in patients with HCM and AF, regardless of CHA ₂ DS ₂ -VA score.	R
Other co-morbidities		
7-13	Request screening for anemia and iron deficiency with complete blood count, serum ferritin concentration and TSAT in all patients with HF.	SR
7-14	Use the standard definition of iron deficiency in HF: ferritin <100 $\mu\text{g/L}$, and if ferritin 100-299 $\mu\text{g/L}$, then TSAT $<20\%$.	SR
7-15	A simplified definition of iron deficiency can be used: TSAT $<20\%$.	R
<i>Resources severely limited</i>	<i>TSAT alone may be used for iron deficiency diagnosis in HF.</i>	

To be continued on next page

No.	Guideline Statement	Level of Recommendation
7-16	Request a formal sleep assessment in patients with HF and suspicion of sleep-disordered breathing, to differentiate between obstructive and central sleep apnea.	R
7-17	Use CPAP/bi-PAP/adaptive servo-ventilation in patients with HF and obstructive sleep apnea, to improve symptoms, sleep quality and daytime sleepiness.	Su
7-18	Use Remede phrenic nerve stimulator in patients with HFrEF and predominant central sleep apnea, to improve symptoms, sleep quality and daytime sleepiness.	Su
7-19	Use GLP-1 RAs based therapies (tirzepatide or semaglutide) in patients with moderate-to-severe OSA and obesity, to reduce apnea-hypopnea index, body weight, and improved sleep-related patient-reported outcomes.	SR
7-20	Do not use adaptive servo-ventilation in patients with NYHA class II to IV HFrEF and central sleep apnea due to increased risk of all-cause and CV mortality.	DND
<i>Resources severely limited</i>	<i>Lifestyle interventions such as diet and exercise may be considered instead of semaglutide or tirzepatide among patients with morbid obesity to reduce weight and improve QoL and symptoms.</i>	
7-21	Use chronic anticoagulation to prevent stroke in patients with HF and permanent-persistent-paroxysmal AF based on CHA ₂ DS ₂ -VA score of ≥ 2 , without differences by gender.	SR
7-22	Use long-term treatment with an oral anticoagulant in patients with HF and AF with a CHA ₂ DS ₂ -VA score of 1, without differences by gender, to decrease the risk of stroke.	R
7-23	Use beta-blockers in patients with HFrEF and AF with high ventricular rate (unless congested), to improve symptoms and control ventricular rate.	R
7-24	Use digoxin in patients with HF and AF with high ventricular rate despite beta-blockers or if beta-blockers are contraindicated, to improve the symptoms and control ventricular rate.	Su
7-25	Use bolus of amiodarone or digoxin in patients with AF with high ventricular rate in NYHA class IV HF, in addition to treatment for AHF, to reduce the ventricular rate.	Su
7-26	Perform catheter ablation in patients with HFrEF and symptoms attributable to AF despite medical therapy, to improve symptoms and QoL.	R

To be continued on next page

No.	Guideline Statement	Level of Recommendation
7-27	Perform AV nodal ablation in patients with HF and LVEF <50%, if rhythm control fails/not desired and ventricular rate remains rapid despite medical therapy, to improve outcomes.	Su
7-28	Do not use class IC antiarrhythmic medications and dronedarone in patients with HFrEF and AF due to increased risk of mortality.	DND
Cardio-oncology		
7-29	Use ACEi or ARB or ARNI, SGLT2 inhibitors and beta-blocker in asymptomatic patients with cancer-therapy-related cardiomyopathy with LVEF <50%, with the aim to decrease the risk of HF and improve cardiac function.	Su
7-30	Establish pretherapy baseline cardiac function in patients with CV risk factors or known cardiac disease who are being considered for potentially cardiotoxic anticancer therapies, to help in selection of cancer therapy.	Su
7-31	Monitor LV function/ global longitudinal strain, LV mass, and cardiac biomarkers (NT-proBNP, troponin, etc.) regularly to allow early detection and management of cardiotoxicity in patients with CV risk factors or known cardiac disease being considered for potentially cardiotoxic anticancer therapies.	Su

Note: the revision of recommendation 7-04 makes the previous recommendation 7-05 redundant.

SR, strongly recommend; R, recommend; Su, suggest; and DND, do not do; ACEi, angiotensin-converting enzyme inhibitors; AHF, acute heart failure; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitors; AF, atrial fibrillation; AS, aortic stenosis; AV, atrioventricular; bi-PAP, bilevel positive airway pressure; CPAP, continuous positive airway pressure; CV, cardiovascular; GDMT, guideline-directed medical therapy; GLP-1RA, glucagon-like peptide 1 receptor agonist; HCM, hypertrophic cardiomyopathy; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; ICD, implantable cardioverter defibrillator; LV, left ventricular; LVEF, left ventricular ejection fraction; LVOT, left ventricular outflow tract; LVOTO, left ventricular outflow tract obstruction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; NSAIDs, non-steroidal anti-inflammatory drugs; NT-proBNP, N-terminal prohormone of B-type natriuretic peptide; OSA, obstructive sleep apnea; PDE5, phosphodiesterase-5; QoL, quality of life; SGLT2, sodium-glucose cotransporter-2; T2DM, type 2 diabetes mellitus; TSAT, transferrin saturation; TTR, transthyretin.

Table 8. Recommendations for special considerations.

No.	Guideline Statement	Level of Recommendation
HF and pregnancy		
8-01	Counsel related to contraception and risks of cardiovascular deterioration during pregnancy in women with a history of HF or cardiomyopathy, including previous peripartum cardiomyopathy.	SR
8-02	Do not use ACEi, ARB, ARNI, MRA, SGLT2 inhibitors, cardiac myosin inhibitors, ivabradine and vericiguat in women with HF or cardiomyopathy, who are pregnant or currently planning for pregnancy because of unclear safety.	DND

To be continued on next page

No.	Guideline Statement	Level of Recommendation
8-03	Use LMWH in the 1 st and 3 rd trimester, and VKA or LMWH for the 2 nd trimester in pregnant women with AF and HF.	R
8-04	Do not use DOACs in pregnant women with HF and AF, due to unclear safety.	DND
8-05	Continue beta-blocker in women with HF or cardiomyopathy who are pregnant or currently planning for pregnancy.	R
8-06	Adjust diuretic dosing in women with HF or cardiomyopathy who are pregnant or currently planning for pregnancy, to minimize the risk of placental hypoperfusion.	R
	Miscellaneous	
8-07	Use fluid restriction to ~2L/d and daily monitoring of body weight in patients with HF and fluid retention not easily controlled with diuretics, to reduce symptoms related to congestion. Avoid a very low target for fluid restriction of 1.5L/d, particularly when patients frequently complain of thirst.	R
8-08A	Influenza vaccination once yearly, preferably with a high-dose vaccine where appropriate, in patients with HF in accordance with local vaccination policies and regional public health recommendations.	SR
8-08B	Pneumococcal vaccination in eligible patients with HF, preferably as a single-dose higher-valent conjugate vaccine (e.g., PCV20 or PCV21) where appropriate, in accordance with regional and national vaccination schedules.	SR
8-08C	Administer COVID-19 vaccination in patients with HF in accordance with current regional and national public health recommendations to reduce the risk of severe infection, hospitalization, and cardiovascular complications.	R
8-08D	Consider herpes zoster vaccination in eligible patients with HF according to age-based and regional vaccination recommendations.	Su
8-08E	Consider respiratory syncytial virus vaccination in eligible patients with HF according to age-based and regional vaccination recommendations.	Su
8-09	Advise exercise training in patients with HF to improve exercise capacity, QoL and reduce the risk of HF hospitalization, if possible.	SR
8-10	Recommend multidisciplinary team care (including a cardiologist, HF nurse, dietitians, and community workers) for high-risk patients with HF during discharge to optimize care.	R
8-11	Counsel and educate patients with HF about the climate/temperature changes, their effects on CV health and mortality, and strategies to reduce those risks.	R

To be continued on next page

No.	Guideline Statement	Level of Recommendation
	Goals of care	
8-12	Use palliative and supportive care focusing on effective communication, conveying prognosis, clarifying goals of care, shared decision-making, symptom management, and caregiver support for HF patients to improve QoL and relieve suffering.	SR

SR, strongly recommend; R, recommend; Su, suggest; DND, do not do; ACEi, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitors; CV, cardiovascular; CVD, cardiovascular disease; DOACs, direct oral anticoagulants; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; LMWH, low molecular weight heparin; MRA, mineralocorticoid receptor antagonist; QoL, quality of life; SGLT2, sodium-glucose cotransporter-2; VKA, vitamin K antagonist.

Table 9. Recommendations for future HF trial design.

No.	Definition	Level of Recommendation
9-01	Future clinical trials in HF should preferentially classify patients as HFrEF (LVEF <50%) or HFpEF (LVEF ≥50%).	R
9-02	Patients with LVEF 41–49% should generally be included within HFrEF trial populations, unless there is a specific scientific rationale otherwise.	R
9-03	Future therapeutic trials may alternatively enroll patients across the entire LVEF spectrum or according to underlying disease phenotypes and evaluate treatment effects continuously rather than using arbitrary EF categories.	Su

R, Recommend; Su, Suggest; HFrEF, Heart Failure with reduced ejection fraction; LVEF, left ventricular ejection fraction; HFpEF, heart failure with preserved ejection fraction.




Figure 1. Recommendations for prevention and diagnosis of heart failure.

SR, strongly recommend; R, recommend; Su, suggest; and DND, Do not do. ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blocker; BNP, brain natriuretic peptide; CMR, cardiac magnetic resonance; CPET, cardiopulmonary exercise training; CT, computed tomography; CVD, cardiovascular disease; CXR, chest X-ray; DPD, 3,3-diphosphono-1,2-propanodicarboxylic acid; GDMT, guideline-directed medical therapy; GLP-1RA, glucagon-like peptide 1 receptor agonist; HF, heart failure; HMDP, hydroxymethylene diphosphonate; NT-proBNP, N-terminal pro-B-type natriuretic peptide; POCUS, point of care ultrasound; PET, positron emission tomography; PYP, pyrophosphate; TTE, transthoracic echocardiography; SGLT2, sodium-glucose co-transporter 2.




Figure 2. Recommendations for the management of heart failure with reduced ejection fraction.

SR, strongly recommend; R, recommend; Su, suggest; and DND, Do not do. ACEi, angiotensin-converting enzyme inhibitors; AF, atrial fibrillation; ARB, angiotensin receptor blocker; AHF, acute heart failure; AR, aortic regurgitation; AS, aortic stenosis; AV, atrioventricular; ARNI, angiotensin receptor neprilysin inhibitor; CABG, coronary artery disease; CABG, coronary artery bypass grafting; COX-2, cyclo-oxygenase-2; CRT, cardiac resynchronization therapy; DPP-4, dipeptidyl peptidase-4; eGFR, estimated glomerular filtration rate; GDMT, guideline-directed medical therapy; HCM, hypertrophic cardiomyopathy; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; ICD, implantable cardioverter-defibrillator; LBbB, left bundle branch block; LVAD, left ventricular assist device; LVEF, left ventricular ejection fraction; MI, myocardial infarction; MR, mitral regurgitation; MRA, mineralocorticoid receptor antagonist; M-TEER, mitral transcatheter edge-to-edge repair; NSAIDs, non-steroidal anti-inflammatory drugs; NT-proBNP, N-terminal prohormone of B-type natriuretic peptide; NYHA, New York Heart Association; PDE5, phosphodiesterase-5; RAAS, Renin-angiotensin-aldosterone system; RV, right ventricle; SGLT2, sodium-glucose co-transporter 2; TSAT, transferrin saturation; TR, tricuspid regurgitation; VAD, ventricular assist device.

Note: In patients with LVEF 40–49%, diagnostic accuracy of test is less certain (due to the variability of LVEF assessments) and the absolute amount of therapeutic benefit of GDMT is somewhat less than in patients with LVEF <40%.

Recommendations for HFpEF Management




Figure 3. Recommendations for the management of heart failure with preserved ejection fraction.

SR, strongly recommend; R, recommend; Su, suggest; and DND, Do not do. ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blocker; ARNI, Angiotensin receptor neprilysin inhibitor; COX-2, cyclo-oxygenase-2; DPP-4, dipeptidyl peptidase-4; GDMT, guideline-directed medical therapy; GLP-1RA, glucagon-like peptide 1 receptor agonist; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; NSAIDs, non-steroidal anti-inflammatory drugs; MRA, mineralocorticoid receptor antagonist; SGLT2, sodium-glucose co-transporter 2.




Figure 4. Recommendations for the management of special conditions in patients with heart failure.

SR, strongly recommend; R, recommend; Su, suggest; and DND, Do not do. ACEi, angiotensin-converting enzyme inhibitors; AF, atrial fibrillation; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; bi-PAP, bilevel positive airway pressure; CPAP, continuous positive airway pressure; DPP-4, dipeptidyl peptidase-4; GDMT, guideline-directed medical therapy; GLP-1RA, glucagon-like peptide 1 receptor agonist; HCM, hypertrophic cardiomyopathy; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; ICD, implantable cardioverter defibrillator; LV, left ventricle; LVOT, left ventricular outflow tract; LVEF, left ventricular ejection fraction; LMWH, low molecular weight heparin; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal prohormone of B-type natriuretic peptide; PDE5, phosphodiesterase-5; SCD, sudden cardiac death; SGLT2, sodium-glucose co-transporter 2, T2DM, type 2 diabetes mellitus; TSAT, transferrin saturation; VKA, vitamin K antagonist.

Note: In patients with LVEF 40–49%, diagnostic accuracy of tests is less certain (due to the variability of LVEF assessments) and the absolute amount of therapeutic benefit of GDMT is somewhat less than in patients with LVEF $< 40\%$.





Figure 5. Overview of HFpEF management.

SR, strongly recommend; R, recommend; Su, suggest; and DND, Do not do. ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; bi-PAP, bilevel positive airway pressure; CV, cardiovascular; CPAP, continuous positive airway pressure; GLP-1RA, glucagon-like peptide 1 receptor agonist; HCM, hypertrophic cardiomyopathy; HFpEF, heart failure with preserved ejection fraction; MRA, mineralocorticoid receptor antagonist; OSA, obstructive sleep apnea; SGLT2, sodium-glucose co-transporter 2.



Adapted from S. Mishra et al. Indian Heart Journal (2018)

Figure 6. Overview of HFrEF management.

SR, strongly recommend; R, recommend; Su, suggest; and DND, Do not do. ACEi, angiotensin-converting enzyme inhibitors; AF, atrial fibrillation; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; bi-PAP, bilevel positive airway pressure; CAD, coronary artery disease; CABG, coronary artery bypass grafting; CRT, cardiac resynchronization therapy; GLP-1RA, glucagon-like peptide 1 receptor agonist; HCM, hypertrophic cardiomyopathy; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; ICD, implantable cardioverter-defibrillator; ISDN, isosorbide dinitrate; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; LVAD, left ventricular assist device; MCS, mechanical circulatory support; MR, mitral regurgitation; MRA, mineralocorticoid receptor antagonist; M-TEER, mitral transcatheter edge-to-edge repair; NT-proBNP, N-terminal prohormone of B-type natriuretic peptide; NYHA, New York Heart Association; OSA, obstructive sleep apnea; SD, sudden death; SGLT2, sodium-glucose co-transporter 2; T2DM, type 2 diabetes mellitus; and TSAT, transferrin saturation.

Note: In patients with LVEF 40–49%, diagnostic accuracy is less certain (due to the variability of LVEF assessments) and the absolute amount of therapeutic benefit of GDMT is somewhat less than in patients with LVEF <40%.

Conflict of interest

See Appendix.

Acknowledgements

The work towards this document is supported by Translational Medicine Academy,⁶² as well as by the iCARDIO Alliance and the iCARDIO Alliance Partner Societies: American Society for Preventive Cardiology, Asian Heart Society, Association of Physicians of India, Canadian Cardiovascular Society, Cardiac Society of Australia and New Zealand, Chinese Heart Failure Association, Ethiopian Society of Cardiac Professionals, Gulf Heart Association, Heart Failure Association of India, Heart Success Foundation, Honduran Association of Cardiology, Hypertension Society of India, Inter-American Society of Cardiology, International College of Cardiology, International Society of Nephrology, Italian Federation of Cardiology, Italian Heart Failure Association, National Heart Failure Committee (China), Obesity Canada, Pan-African Society of Cardiology, Roland Hertz International Cardiothoracic & Vascular Surgery Society, Arrhythmia Alliance, Global Heart Hub, Heart Life Foundation (see also: <https://icardioalliance.org/partner-societies/>).

We sincerely thank all those who participated in the public review for their valuable feedback and contributions. Their time, expertise, and insights have been instrumental in strengthening this document.

Editorial Support was provided by MediCog LLC.

Disclaimer

This document expresses the opinions of its authors at the time it was published. Its content reflects the scientific evidence, existing guidelines, and implementation considerations, including economic factors, known at the date of publication. The iCARDIO Alliance, its Partner Organizations, and the TMA accept no liability for any inconsistency between this document and recommendations issued by other organizations or authorities. The document is intended to support, not replace, clinical judgement. Treatment decisions remain the responsibility of the treating health professional and should be made for each patient individually, together with the patient and, where relevant, the caregiver. Health professionals must also follow the recommendations of the public health authorities responsible for them and confirm the current regulatory status of any drug or medical device before prescribing.

Author information

Task Force Member Affiliations:

Vijay Chopra, Heart Failure Programme and Research, Max

Super Specialty Hospital, Saket, New Delhi, Delhi, India; **William T. Abraham**, Division of Cardiovascular Medicine and The Davis Heart and Vascular Research Institute, The Ohio State University (OSU) College of Medicine and OSU Wexner Medical Center, Columbus, Ohio, USA; **Offer Amir**, Heart Institute, Hadassah Medical Center & Hebrew University, Jerusalem, Israel; **Stefan D. Anker**, Department of Cardiology (CVK) of German Heart Center Charité; German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin, Berlin, Germany; **John J. Atherton**, University of Queensland Faculty of Health, Medicine and Behavioural Sciences, Cardiology Department, Royal Brisbane and Women's Hospital, Herston, Brisbane, QLD, Australia **Fernando Bacal**, Heart Institute (InCor), University of Sao Paulo, Medical School, Brazil; Hospital Israelita Albert Einstein, São Paulo, Brazil; **Ralph Stephan von Bardeleben**, Department of Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany; **Dulce Brito**, Cardiology Department, ULSSM, Hospital de Santa Maria, CCUL@RISE, Lisboa, Portugal; **Lucrecia Maria Burgos**, Heart Failure, Pulmonary Hypertension and Heart Transplantation Department, Instituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina; **Javed Butler**, Department of Medicine, University of Mississippi Medical Centre, Jackson, Mississippi, USA; Baylor Scott and White Research Institute, Dallas, Texas, USA; **Maria Rosa Costanzo**, Midwest Cardiovascular Institute, Naperville, Illinois, USA; **Albertino Damasceno**, Faculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique; **Justin A. Ezekowitz**, University of Alberta, Edmonton, Canada; **Ishaque Hameed**, Department of Medicine, MedStar Health, Baltimore, Maryland, USA; **Sivadasanpillai Harikrishnan**, Department of Cardiology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, Kerala, India; **Anuradha Lala**, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine, New York, USA; **Ileana L. Piña**, Thomas Jefferson University, Philadelphia, Pennsylvania, USA; **Clara Saldarriaga**, Clinica CardioVID, University of Antioquia, Medellin, Colombia; **David Sim**, National Heart Centre Singapore, Singapore; **John R. Teerlink**, Section of Cardiology, San Francisco Veterans Affairs Medical Center, San Francisco, California, USA; School of Medicine, University of California San Francisco, San Francisco, California, USA; **Nqoba Tsabedze**, Division of Cardiology, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand and the Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa; **Hiroyuki Tsutsui**, International University of Health and Welfare, Fukuoka, Japan; **Jing Yu**, Heart Failure Center, Department of Cardiology, Lanzhou University Second Hospital, Lanzhou, Gansu, China; **Yuhui Zhang**, Heart Failure Center, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China; **Mohammad Zubaid**, Department of Medicine, Faculty of Medicine, Kuwait University, Kuwait.

Reviewer Affiliations:

Nikhil Balankhe, Department of Medicine and Critical Care

Medicine, Viveka Hospitals, Nagpur, Maharashtra, India; **John G.F. Cleland**, University of Glasgow, United Kingdom; **Gemma Figtree**, Department of Cardiology, Royal North Shore Hospital, St Leonards, New South Wales, Australia; Faculty of Medicine and Health, The University of Sydney, Camperdown, New South Wales, Australia; **Gerasimos Filippatos**, Department of Cardiology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, Rimini 1, Chaidari, Athens 12462, Greece; **Marat Fudim**, Division of Cardiology, Duke University School of Medicine, Durham, North Carolina, USA; Duke Clinical Research Institute, Durham, North Carolina, USA; **Habib Gamra**, Faculty of Medicine, University of Monastir, Tunisia; **Juan Esteban Gomez-Mesa**, Servicio de Cardiología, Fundación Valle del Lili, Cali, Colombia; Departamento de Ciencias de la Salud, Universidad Icesi, Cali, Colombia; **Martha Gulati**, The Davis Women's Heart Center, Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, Houston, Texas, USA; **James L. Januzzi**, Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Baim Institute for Clinical Research, Boston, Massachusetts, USA; **Marvin A. Konstam**, The CardioVascular Center, Tufts Medical Center, and Tufts University School of Medicine, Boston, Massachusetts, USA; **JoAnn Lindenfeld**, Advanced Heart Failure, Vanderbilt Heart and Vascular Institute, Nashville, Tennessee, USA; **Robert J. Mentz**, Duke University School of Medicine, Durham, North Carolina, USA; **Rhonda Monroe**, Better Outcomes Optimal Scientific Therapies (BOOST), Washington D.C., USA; **Elijah Ogola**, Department of Clinical Medicine and Therapeutics, Faculty of Health Sciences, University of Nairobi, Kenya; **Fausto J. Pinto**, Centro Academico de Medicina de Lisboa, CCUL@RISE, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal; **Girish C. Rajadhyaksha**, Department of Medicine, Topiwala National Medical College & B.Y.L. Nair Ch Hospital, Mumbai, Maharashtra, India; **Carlos E. Ramos**, Instituto Nacional Cardiopulmonar, Tegucigalpa, Honduras; **Giuseppe Rosano**, IRCCS San Raffaele Roma, Rome, Italy; San Raffaele University, Rome, Italy; **Victor Rossel**, Council of Heart Failure and Pulmonary Hypertension, Inter-American Society of Cardiology, México; Hospital del Salvador/Faculty of Medicine, University of Chile, Santiago, Chile; **Naoki Sato**, Department of Cardiovascular Medicine, Kawaguchi Cardiovascular and Respiratory Hospital, Kawaguchi, Japan; **P. Christian Schulze**, Department of Internal Medicine I, Cardiology, University Hospital Jena, Jena, Germany; **Andrew Sindone**, Heart Failure Unit and Department of Cardiac Rehabilitation, Concord Hospital and Department of Cardiology, Ryde Hospital, Sydney, Australia; **Kadhim Sulaiman**, National Heart Center, Royal Hospital, Muscat, Oman; **Muthiah Vaduganathan**, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA; **Harriette G.C. Van Spall**, Department of Medicine, Department of Health Research Methods Evidence, and Impact, Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada; **Dirk J. van Veldhuisen**, Department of

Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; **Stephan von Haehling**, Department of Cardiology and Pneumology, German Center for Cardiovascular Research (DZHK), partner site Lower Saxony, University Göttingen Medical Center, Göttingen, Germany; **Tzung-Dau Wang**, Cardiovascular Center and Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei City, Taiwan; **Pepe Zamorano**, University Hospital Ramón y Cajal, Madrid, Spain; **Michael Böhm**, Universitätsklinikum des Saarlandes, HOMICAREM (HOMburg Institute for CARDioREnalMetabolic Medicine), Klinik für Innere Medizin III, Saarland University, Homburg/Saar, Germany; **Andrew J.S. Coats**, Heart Research Institute, Sydney, Australia; **Shelley Zieroth**, University of Manitoba, St. Boniface Hospital, Cardiac Sciences Manitoba, Canada.

Additional Document Reviewers:

John McMurray, University of Glasgow, Glasgow, United Kingdom; **Clyde Yancy**, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

References

1. Tromp J, Bamadhaj S, Cleland JGF, et al. Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study. *Lancet Glob Health* 2020;8:e411-22.
2. Virani SS, Alonso A, Aparicio HJ, et al. Heart disease and stroke statistics-2021 update: a report from the American Heart Association. *Circulation* 2021;143:e254-e743.
3. Bozkurt B, Ahmad T, Alexander K, et al. HF STATS 2024: heart failure epidemiology and outcomes statistics: an updated 2024 report from the Heart Failure Society of America. *J Card Fail* 2025;31:66-116.
4. No authors listed. Heart failure: management of patients with left-ventricular systolic dysfunction. *Clin Pract Guidel Quick Ref Guide Clin* 1994;11:1-21.
5. No authors listed. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). *Circulation* 1995;92:2764-84.
6. Heidenreich PA, Bozkurt B, Aguilar D. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation* 2022;145:e895-1032.
7. Kittleston MM, Panjath GS, Amancherla K, et al. 2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol* 2023;81:1835-78.
8. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* 2021;42:3599-726.
9. McDonagh TA, Metra M, Adamo M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* 2023;44:3627-39.

10. National Guideline Centre (UK). Chronic heart failure in adults: diagnosis and management. London: National Institute for Health and Care Excellence (NICE); 2018.
11. No authors listed. Acute heart failure: diagnosis and management. London: National Institute for Health and Care Excellence (NICE).
12. NHFA CSANZ Heart Failure Guidelines Working Group; Atherton JJ, Sindone A, et al. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: guidelines for the prevention, detection, and management of heart failure in Australia 2018. *Heart Lung Circ* 2018;27:1123-208.
13. McDonald M, Virani S, Chan M, et al. CCS/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction. *Can J Cardiol* 2021;37:531-46.
14. Ezekowitz JA, O'Meara E, McDonald MA, et al. 2017 comprehensive update of the Canadian Cardiovascular Society guidelines for the management of heart failure. *Can J Cardiol* 2017;33:1342-433.
15. Tsutsui H, Isobe M, Ito H, et al. JCS 2017/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure: digest version. *Circ J* 2019;83:2084-184.
16. Tsutsui H, Ide T, Ito H, et al. JCS/JHFS 2021 guideline focused update on diagnosis and treatment of acute and chronic heart failure. *J Card Fail* 2021;27:1404-44.
17. Heart Failure Group of Chinese Society of Cardiology of Chinese Medical Association, Chinese Heart Failure Association of Chinese Medical Doctor Association, Editorial Board of Chinese Journal of Cardiology. Chinese guidelines for the diagnosis and treatment of heart failure 2018. *Zhonghua Xin Xue Guan Bing Za Zhi* 2018;46:760-89.
18. Guha S, Harikrishnan S, Ray S, et al. CSI position statement on management of heart failure in India. *Indian Heart J* 2018;70:S1-72.
19. Huffman MD, Roth GA, Sliwa K, et al. Chapter 10 - heart failure. In: Prabhakaran D, Anand S, Gaziano TA, Mbanya JC, Wu Y, Nugent R, editors. Cardiovascular, respiratory, and related disorders. 3rd ed. The International Bank for Reconstruction and Development/The World Bank; 2017.
20. Zubaid M, Rashed W, Ridha M, et al. Implementation of guideline-recommended therapies for patients with heart failure and reduced ejection fraction: a regional Arab Middle East experience. *Angiology* 2020;71:431-7.
21. Zubaid M, Rashed W, Ridha M, et al. Design and rationale of Gulf Documentation of Ambulatory Sick Patients with Heart Failure (Gulf DYSYPNEA) registry. *Heart Views* 2018;19:81-4.
22. Al Habeeb W, Tash A, Elsfar A, et al. 2023 National Heart Center/Saudi Heart Association focused update of the 2019 Saudi Heart Association guidelines for the management of heart failure. *J Saudi Heart Assoc* 2023;35:71-134.
23. Bragazzi NL, Zhong W, Shu J, et al. Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017. *Eur J Prev Cardiol* 2021;28:1682-90.
24. Sulaiman K, Panduranga P, Al-Zakwani I, et al. Clinical characteristics, management, and outcomes of acute heart failure patients: observations from the Gulf acute heart failure registry (Gulf CARE). *Eur J Heart Fail* 2015;17:374-84.
25. Damasceno A, Mayosi BM, Sani M, et al. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. *Arch Intern Med* 2012;172:1386-94.
26. Joseph P, Dokainish H, McCready T, et al. A multinational registry to study the characteristics and outcomes of heart failure patients: the global congestive heart failure (G-CHF) registry. *Am Heart J* 2020;227:56-63.
27. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet* 2004;364:937-52.
28. Chopra V, Khan MS, Abdelhamid M, et al. iCARDIO Alliance global implementation guidelines on heart failure 2025. *Global Cardiol* 2025;3:47-74.
29. Chopra V, Abraham WT, Amir O, et al. What is new and what has changed in the 2026 Global Heart Failure Implementation Guidelines and why. *Global Cardiology* 2026;4:197-214. DOI: 10.4081/cardio.2026.118.
30. Anker SD, Friede T, von Bardeleben RS, et al. Transcatheter valve repair in heart failure with moderate to severe mitral regurgitation. *N Engl J Med* 2024;391:1799-809.
31. von Bardeleben RS, Khan MS, Geyer M, et al. Baseline echocardiographic characteristics of patients enrolled in the randomized investigation of MitraClip device in heart failure (RESHAPE HF-2) trial: comparison with COAPT and Mitra-FR. *Global Cardiology* 2024;2:125-32. DOI: 10.4081/cardio.2024.40.
32. Anker SD, Butler J, Talha KM, Friede T. Using multiple primary endpoints in clinical trials with a focus on heart failure. *Global Cardiology* 2024;2:69-74. DOI: 10.4081/cardio.2024.33.
33. Anker MS, Porthun J, Bonnet G, et al. Baseline echocardiographic characteristics of patients enrolled in the randomized investigation percutaneous transcatheter edge-to-edge repair for functional mitral regurgitation in heart failure: a meta-analysis of 3 randomized controlled trials. *J Am Coll Cardiol* 2024;84:2364-8.
34. Brugs JJ, Radhoe SP, Clephas PRD, et al. Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial. *Lancet* 2023;401:2113-23.
35. Boehmer JP, Cremer S, Abo-Auda WS, et al. Impact of a novel wearable sensor on heart failure rehospitalization: an open-label concurrent-control clinical trial. *JACC Heart Fail* 2024;12:2011-22.
36. Kar S, Makkar RR, Whisenant BK, et al. Two-year outcomes of transcatheter edge-to-edge repair for severe tricuspid regurgitation: the TRILUMINATE PIVOTAL randomized trial. *Circulation* 2025;151:1630-38.
37. Anker SD, Friede T, Butler J, et al. Intravenous ferric carboxymaltose in heart failure with iron deficiency: the FAIR-HF2 DZHK05 randomized clinical trial. *JAMA* 2025;333:1965-76.
38. Anker SD, Karakas M, Mentz RJ, et al. Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency. *Nat Med* 2025;31:2640-46.
39. Talha KM, Butler J, von Haehling S, et al. Defining iron replete status in patients with heart failure treated with intravenous iron. *Global Cardiology* 2023; 1: 7-11. DOI: 10.4081/cardio.2023.17.
40. Gillmore JD, Judge DP, Cappelli F, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. *N Engl J Med* 2024;390:132-42.
41. Judge DP, Alexander KM, Cappelli F, et al. Efficacy of acoramidis on all-cause mortality and cardiovascular hospitalization in transthyretin amyloid cardiomyopathy. *J Am Coll Cardiol* 2025;85:1003-14.
42. Fontana M, Berk JL, Gillmore JD, Witteles RM, et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. *N Engl J Med* 2025;392:33-44.
43. Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. *N Engl J Med* 2024;391:1475-85.
44. Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. *N Engl J Med* 2023;389:1069-84.
45. Kosiborod MN, Petrie MC, Borlaug BA, et al. Semaglutide in pa-

- tients with obesity-related heart failure and type 2 diabetes. *N Engl J Med* 2024;390:1394-407.
46. Butler J, Shah SJ, Petrie MC, et al. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. *Lancet* 2024;403:1635-48.
 47. Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. *N Engl J Med* 2025;392:427-37.
 48. Herrmann JJ, Brunner-La Rocca HP, Baltussen LEHJM, et al. Liberal fluid intake versus fluid restriction in chronic heart failure: a randomized clinical trial. *Nat Med* 2025;31:2062-8.
 49. van Veldhuisen DJ, Rienstra M, Mosterd A, et al. Low-dose digoxin in patients with heart failure with reduced or mildly reduced ejection fraction: a randomized controlled trial. *Nat Med*. 2026;32:2647-53.
 50. Bavendiek U, Großhennig A, Schwab J, et al. Digitoxin in patients with heart failure and reduced ejection fraction. *N Engl J Med* 2025;393:1155-65.
 51. Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. *N Engl J Med* 2020;382:1883-93.
 52. Butler J, Fioretti F, McMullan CJ, et al. Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial. *Eur Heart J* 2026;47:683-97.
 53. Damman K, van Veldhuisen DJ, Bauersachs J, et al. Efficacy and safety of digitalis glycosides in heart failure: a meta-analysis. *JAMA* 2026;335:2029-37.
 54. Desai MY, Owens AT, Abraham T, et al. Mavacamten in symptomatic nonobstructive hypertrophic cardiomyopathy. *N Engl J Med* 2025;393:961-72.
 55. Modin D, Jørgensen ME, Gislason G, et al. Influenza vaccine in heart failure. *Circulation* 2019;139:575-86.
 56. Johansen ND, Modin D, Pardo-Seco J, et al. High-dose versus standard-dose influenza vaccine and cardiovascular outcomes in older adults: the FLUNITY-HD prespecified pooled analysis. *Circulation* 2026;153:798-806.
 57. Kobayashi M, Leidner AJ, Gierke R, et al. Use of 21-valent pneumococcal conjugate vaccine among US adults: recommendations of the Advisory Committee on Immunization Practices - United States, 2024. *MMWR Morb Mortal Wkly Rep* 2024;73:793-8.
 58. Akbar UA, Thyagaturu H, Taha A, et al. COVID-19 vaccination and cardiovascular outcomes in older adults with coronary artery disease and heart failure: insights from a large propensity-matched cohort study. *J Am Heart Assoc* 2025;14:e044546.
 59. Skaarup KG, Lassen MCH, Johansen ND, et al. Effect of RSV vaccine on heart failure hospitalizations: a prespecified analysis of the DAN-RSV trial. *J Am Coll Cardiol* 2025;86:2062-7.
 60. Masri A, Maron MS, Bhatia A, et al. Aficamten for symptomatic nonobstructive hypertrophic cardiomyopathy. *N Engl J Med*. 2026 Aug 28. DOI: 10.1056/NEJMoa2603021. (Online ahead of print.)
 61. Prata AA, Katsuyama ES, Scardini PG, et al. The efficacy and safety of specific therapies for cardiac Transthyretin-mediated amyloidosis: a systematic review and meta-analysis of randomized trials. *BMC Cardiovasc Disord* 2025;25:296.
 62. Pinto FJ, Anker SD, Abraham WT, et al. The Global Implementation Guidelines Initiative: how to optimize cardio-renal-metabolic care worldwide. *Global Cardiology* 2025;3:37-41. DOI: 10.4081/cardio.2025.68.